Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains a significant public health challenge and is currently the fourth leading cause of cancer-related mortality in developed countries. Despite advances in cancer treatment, the 5-year survival rate for patients with PDAC remains less than 5%. In recent ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Bo, Zhang, Shi-Ran, Chen, Geng, Chen, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514760/
https://www.ncbi.nlm.nih.gov/pubmed/37744290
http://dx.doi.org/10.3748/wjg.v29.i35.5094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514760/
https://www.ncbi.nlm.nih.gov/pubmed/37744290
http://dx.doi.org/10.3748/wjg.v29.i35.5094

Ejemplares similares